文献速递肿瘤 PET/CT

PET/CT用于分期:过去、现在与未来

PET/CT for Staging; Past, Present, and Future.
PubMed 文献 · Semin Nucl Med · 2017-09-21

淋巴瘤分期影响治疗决策,影像学是分期最重要决定因素。本文综述淋巴瘤分期历史与目的,指出2014年卢加诺分类推荐PET/CT用于所有FDG亲和性淋巴瘤的常规分期,并讨论PET/CT替代常规骨髓活检的争议。

要点

  • 2014年卢加诺分类推荐PET/CT用于所有FDG亲和性淋巴瘤的常规分期。
  • 霍奇金淋巴瘤及部分弥漫大B细胞淋巴瘤不再鼓励常规骨髓活检。
  • PET/CT诊断准确性优于单独CT,已改变淋巴瘤分期实践。

核心结论

  • PET/CT用于淋巴瘤分期已带来分期概念与实践的实质性变化,2014年卢加诺分类是最新的专家推荐。

研究设计与样本

  • 综述,检索范围与样本量原文未报告。

主要发现

  • 疾病分期在多数淋巴瘤亚型中比其他临床信息更显著影响治疗决策,并单独或作为临床预后评分的一部分提供重要预后信息。
  • 医学影像信息是疾病分期的单一最重要决定因素。
  • 淋巴瘤分期最重要的变化是放弃原安娜堡分类中意图进行的广泛病理分期。

关键数值与推荐

  • 2014年卢加诺分类推荐PET/CT用于所有FDG亲和性淋巴瘤的常规分期。
  • 霍奇金淋巴瘤及部分弥漫大B细胞淋巴瘤病例不鼓励常规骨髓活检。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accurate and reproducible staging is crucial for management of malignant lymphomas. Disease stage influences treatment decisions more significantly than any other clinical information in most lymphoma subtypes, and contributes with important prognostic information on its own or as part of clinical prognostic scores. Information derived from medical imaging is the single most important determinant of disease stage, and the introduction PET/CT for lymphoma has led to substantial changes in the concept as well as practice of lymphoma staging. Over time, the most important change in lymphoma staging has been the abandonment of extensive pathologic staging intended in the original Ann Arbor classification. The 2014 Lugano Classification represents the most recent expert recommendation for staging of lymphoma. This revision recognizes the improved diagnostic accuracy of PET/CT over stand-alone CT and recommended PET/CT for routine staging of all FDG-avid lymphomas. Routine bone marrow biopsies are also discouraged in Hodgkin lymphoma as well as in selected cases of diffuse large B-cell lymphoma. The scope of this review is to give the reader insight into the history of staging, the purpose of lymphoma staging in the context of contemporary treatment strategies, and the advantages of PET/CT staging over conventional staging. We also discuss the controversies of PET/CT replacing conventional bone marrow biopsies in different lymphoma subtypes and summarize recommendations by the recent Lugano classification.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. El-Galaly TC, Gormsen LC, Hutchings M, et al. PET/CT for Staging; Past, Present, and Future. Semin Nucl Med. 2017. PMID: 29195617. doi:10.1053/j.semnuclmed.2017.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。